Home / Intelligence / White Papers / Solving a Pervasive Challenge: Breaking Down Silos in Life Sciences
Experts at Trinity Life Sciences interact with the inner workings of pharma from many perspectives as they engage with teams across life sciences organizations.
A common observation is that teams are working in silos: often unaware of what other teams are doing, sometimes pulling in different directions and frequently experiencing frustrations.
Internally, siloed working can create delays, unnecessary budget burn and re-work. Externally, it can result in negative coverage decisions or market underperformance, which ultimately impacts the patient. In some cases, there is nominal inclusion, but the opportunities for true synergy are rarely captured.
Through experience over nearly 30 years, Trinity’s experts have found that malaise or tension between teams can be solved by developing core strategies and functional plans that involve the right people, address the intersectionality required for success and take a long-term view.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Virtual Demo | HTA Vision with GenAI
March 13, 2025 | 11:00 – 11:30 AM ET
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities. It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future […]
Sign Up Now
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More